JP7857080B2 - 破傷風神経毒素に結合する単一ドメイン抗体 - Google Patents
破傷風神経毒素に結合する単一ドメイン抗体Info
- Publication number
- JP7857080B2 JP7857080B2 JP2020545344A JP2020545344A JP7857080B2 JP 7857080 B2 JP7857080 B2 JP 7857080B2 JP 2020545344 A JP2020545344 A JP 2020545344A JP 2020545344 A JP2020545344 A JP 2020545344A JP 7857080 B2 JP7857080 B2 JP 7857080B2
- Authority
- JP
- Japan
- Prior art keywords
- sda
- tent
- sdas
- binding
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1282—Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023191811A JP2024023268A (ja) | 2018-03-13 | 2023-11-09 | 破傷風神経毒素に結合する単一ドメイン抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18161521 | 2018-03-13 | ||
| EP18161521.2 | 2018-03-13 | ||
| PCT/EP2019/056299 WO2019175250A1 (en) | 2018-03-13 | 2019-03-13 | Single domain antibodies binding to tetanus neurotoxin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023191811A Division JP2024023268A (ja) | 2018-03-13 | 2023-11-09 | 破傷風神経毒素に結合する単一ドメイン抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021516682A JP2021516682A (ja) | 2021-07-08 |
| JP7857080B2 true JP7857080B2 (ja) | 2026-05-12 |
Family
ID=61691657
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020545344A Active JP7857080B2 (ja) | 2018-03-13 | 2019-03-13 | 破傷風神経毒素に結合する単一ドメイン抗体 |
| JP2023191811A Pending JP2024023268A (ja) | 2018-03-13 | 2023-11-09 | 破傷風神経毒素に結合する単一ドメイン抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023191811A Pending JP2024023268A (ja) | 2018-03-13 | 2023-11-09 | 破傷風神経毒素に結合する単一ドメイン抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12054540B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3765495A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7857080B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN117964751A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019233603B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020018563A2 (cg-RX-API-DMAC7.html) |
| MA (1) | MA51996A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2020009507A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019175250A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202403355B (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113248610B (zh) * | 2021-05-14 | 2022-08-16 | 厦门柏慈生物科技有限公司 | 白细胞介素2结合分子、其衍生物、试剂盒及其生产方法和用途 |
| AU2022287910A1 (en) * | 2021-06-07 | 2023-12-14 | Michael L. MARTINO | Rapid recognition based diagnosis and treatment |
| CN117624360A (zh) * | 2022-08-26 | 2024-03-01 | 南京融捷康生物科技有限公司 | 一种抗trem2的单域抗体及其用途 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003503059A (ja) | 1999-06-25 | 2003-01-28 | インペリアル カレッジ オブ サイエンス, テクノロジー アンド メディシン | 破傷風毒素ポリペプチド |
| JP2009524641A (ja) | 2006-01-25 | 2009-07-02 | エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム | 対立遺伝子排除 |
| JP2011504740A (ja) | 2007-11-27 | 2011-02-17 | アブリンクス エン.ヴェー. | ヘテロ二量体サイトカイン及び/又はこれらの受容体に指向性を有するアミノ酸配列、並びにこれを含むポリペプチド |
| JP2016528884A (ja) | 2013-06-28 | 2016-09-23 | メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー | 細胞において神経毒ポリペプチドの生物活性を決定する手段及び方法 |
| WO2016187594A1 (en) | 2015-05-21 | 2016-11-24 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| JP2017538414A (ja) | 2014-12-09 | 2017-12-28 | ニューヨーク・ユニバーシティ | クロストリジウム神経毒融合タンパク質、プロペプチド融合体、それらの発現及び使用方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| EP0698097B1 (en) | 1993-04-29 | 2001-08-16 | Unilever N.V. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
| EP0739981A1 (en) * | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| AUPS022802A0 (en) * | 2002-01-31 | 2002-02-21 | Macfarlane Burnet Institute For Medical Research And Public Health Limited, The | Anti-viral compounds |
| AU2004245429A1 (en) | 2003-06-10 | 2004-12-16 | Farallone Holding Bv | Binding peptides: methods for their generation and use |
| CN102875681A (zh) * | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
| CN101386648B (zh) * | 2008-09-25 | 2012-05-30 | 中国人民解放军军事医学科学院微生物流行病研究所 | 抗b型肉毒神经毒素中和性单克隆抗体、其制备方法及用途 |
| AU2010267963B2 (en) * | 2009-07-02 | 2015-09-24 | Merz Pharma Gmbh & Co. Kgaa | Neurotoxins exhibiting shortened biological activity |
| WO2011064382A1 (en) | 2009-11-30 | 2011-06-03 | Ablynx N.V. | Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
| SI3339323T1 (sl) * | 2010-08-12 | 2019-12-31 | Eli Lilly And Company | Protitelesa proti N3PGLU amiloid beta peptidu in njihove uporabe |
| US9409950B2 (en) | 2010-12-23 | 2016-08-09 | Biogen Ma Inc. | Linker peptides and polypeptides comprising same |
| JP6162135B2 (ja) * | 2011-11-09 | 2017-07-12 | メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー | 短縮された生物活性を示す神経毒 |
| WO2013110531A1 (en) * | 2012-01-23 | 2013-08-01 | Ablynx Nv | Sequences directed against hepatocyte growth factor (hgf) and polypeptides comprising the same for the treatment of cancers and/or tumors |
| WO2013157105A1 (ja) * | 2012-04-18 | 2013-10-24 | 公立大学法人大阪市立大学 | ムチンサブタイプ5ac特異的ヒト化抗体およびその利用 |
| US10668147B2 (en) * | 2015-03-25 | 2020-06-02 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. | Anti-CD89 cytotoxic complex |
-
2019
- 2019-03-13 MA MA051996A patent/MA51996A/fr unknown
- 2019-03-13 EP EP19710685.9A patent/EP3765495A1/en active Pending
- 2019-03-13 JP JP2020545344A patent/JP7857080B2/ja active Active
- 2019-03-13 AU AU2019233603A patent/AU2019233603B2/en active Active
- 2019-03-13 WO PCT/EP2019/056299 patent/WO2019175250A1/en not_active Ceased
- 2019-03-13 BR BR112020018563-9A patent/BR112020018563A2/pt unknown
- 2019-03-13 MX MX2020009507A patent/MX2020009507A/es unknown
- 2019-03-13 CN CN202410029937.5A patent/CN117964751A/zh active Pending
- 2019-03-13 CN CN201980018808.3A patent/CN112135840B/zh active Active
- 2019-03-13 US US16/978,714 patent/US12054540B2/en active Active
-
2020
- 2020-09-11 MX MX2025004782A patent/MX2025004782A/es unknown
-
2023
- 2023-11-09 JP JP2023191811A patent/JP2024023268A/ja active Pending
-
2024
- 2024-04-30 US US18/650,282 patent/US20240376185A1/en active Pending
- 2024-04-30 ZA ZA2024/03355A patent/ZA202403355B/en unknown
-
2025
- 2025-09-19 AU AU2025234234A patent/AU2025234234A1/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003503059A (ja) | 1999-06-25 | 2003-01-28 | インペリアル カレッジ オブ サイエンス, テクノロジー アンド メディシン | 破傷風毒素ポリペプチド |
| JP2009524641A (ja) | 2006-01-25 | 2009-07-02 | エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム | 対立遺伝子排除 |
| JP2011504740A (ja) | 2007-11-27 | 2011-02-17 | アブリンクス エン.ヴェー. | ヘテロ二量体サイトカイン及び/又はこれらの受容体に指向性を有するアミノ酸配列、並びにこれを含むポリペプチド |
| JP2016528884A (ja) | 2013-06-28 | 2016-09-23 | メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー | 細胞において神経毒ポリペプチドの生物活性を決定する手段及び方法 |
| JP2017538414A (ja) | 2014-12-09 | 2017-12-28 | ニューヨーク・ユニバーシティ | クロストリジウム神経毒融合タンパク質、プロペプチド融合体、それらの発現及び使用方法 |
| WO2016187594A1 (en) | 2015-05-21 | 2016-11-24 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
Non-Patent Citations (2)
| Title |
|---|
| FEBS Letters, 1997年, Vol.414, pp.521-526 |
| mAbs, 2015年, Vol.7, No.5, pp.820-828 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024023268A (ja) | 2024-02-21 |
| US20220275066A1 (en) | 2022-09-01 |
| AU2019233603B2 (en) | 2025-06-26 |
| US12054540B2 (en) | 2024-08-06 |
| MX2020009507A (es) | 2020-10-22 |
| CN112135840B (zh) | 2024-01-23 |
| ZA202403355B (en) | 2024-12-18 |
| US20240376185A1 (en) | 2024-11-14 |
| MX2025004782A (es) | 2025-05-02 |
| JP2021516682A (ja) | 2021-07-08 |
| CN112135840A (zh) | 2020-12-25 |
| CN117964751A (zh) | 2024-05-03 |
| MA51996A (fr) | 2021-01-20 |
| BR112020018563A2 (pt) | 2020-12-29 |
| EP3765495A1 (en) | 2021-01-20 |
| AU2025234234A1 (en) | 2025-10-09 |
| WO2019175250A1 (en) | 2019-09-19 |
| AU2019233603A1 (en) | 2020-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7241731B2 (ja) | 血清アルブミン結合剤 | |
| US20240376185A1 (en) | Tetanus prophylaxis | |
| US9850315B2 (en) | Antigen-binding protein directed against epitope in the CH1 domain of human IgG antibodies | |
| US20240132624A1 (en) | Polypeptides binding to a specific epitope of the neonatal fc receptor | |
| US20240368250A1 (en) | Polypeptides binding to the neonatal fc receptor | |
| US20210347868A1 (en) | Anti-synuclein antibodies | |
| US20250129145A1 (en) | Bi- and multivalent albumin binders | |
| Rossotti et al. | Increasing the potency of neutralizing single-domain antibodies by functionalization with a CD11b/CD18 binding domain | |
| CN113631579B (zh) | 组织纤溶酶原激活物抗体及其使用方法 | |
| WO2024084203A1 (en) | Single domain antibodies binding to albumin | |
| Harmsen et al. | Serum immunoglobulin or albumin binding single-domain antibodies that enable tailored half-life extension of biologics in multiple animal species | |
| Traxlmayr et al. | Integrin binding human antibody constant domains—Probing the C-terminal structural loops for grafting the RGD motif | |
| WO2025219585A1 (en) | Vhh antibodies which bind to canine albumin | |
| JP2025525566A (ja) | Cx3cr1結合化合物、その使用及び関連する方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20201019 |
|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20201019 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220310 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230125 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230131 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230428 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230711 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231109 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20231114 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20240112 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260121 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260424 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7857080 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |